Ulcerative Colitis, New England Journal of Medicine, vol.365, issue.18, pp.1713-1738, 2011. ,
DOI : 10.1056/NEJMra1102942
URL : https://hal.archives-ouvertes.fr/hal-01303796
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.6, issue.10, pp.965-90, 2012. ,
DOI : 10.1016/j.crohns.2012.09.003
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management, Journal of Crohn's and Colitis, vol.6, issue.10, pp.991-1030, 2012. ,
DOI : 10.1016/j.crohns.2012.09.002
Thiopurines in inflammatory bowel disease revisited, World Journal of Gastroenterology, vol.19, issue.11, pp.1699-706, 2013. ,
DOI : 10.3748/wjg.v19.i11.1699
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.369, issue.8, pp.699-710, 2013. ,
DOI : 10.1056/NEJMoa1215734
Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs, World Journal of Gastroenterology, vol.20, issue.29, pp.9699-715, 2014. ,
DOI : 10.3748/wjg.v20.i29.9699
Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?, Clinical and Experimental Gastroenterology, vol.6, pp.1-7, 2013. ,
DOI : 10.2147/CEG.S33275
Multivariate Analysis for Factors Predicting Rapid Response of Leukocytapheresis in Patients With Steroid-resistant Ulcerative Colitis: A Multicenter Prospective Open-label Study, Therapeutic Apheresis and Dialysis, vol.165, issue.Suppl. 1, pp.484-90, 2008. ,
DOI : 10.1111/j.1744-9987.2008.00639.x
The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review, Clinical & Experimental Immunology, vol.23, issue.2, pp.50-58, 2011. ,
DOI : 10.1111/j.1365-2249.2010.04279.x
A Role for Granulocyte and Monocyte Apheresis in the Treatment of Rheumatoid Arthritis, Therapeutic Apheresis, vol.100, issue.1, pp.134-175, 1998. ,
DOI : 10.1111/j.1744-9987.1998.tb00091.x
Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes, Therapeutic Apheresis and Dialysis, vol.52, issue.1, pp.48-59, 2003. ,
DOI : 10.1016/0014-5793(95)01036-E
Clinical Effectiveness of Selective Granulocyte, Monocyte Adsorptive Apheresis with the Adacolumn?? Device in Ulcerative Colitis, Digestive Diseases and Sciences, vol.8, issue.Suppl 1, pp.1421-1429, 2010. ,
DOI : 10.1007/s10620-009-0845-x
Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.327, issue.11-12, pp.1297-306, 2010. ,
DOI : 10.1111/j.1365-2036.2010.04490.x
URL : https://hal.archives-ouvertes.fr/hal-00585782
The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis, International Journal of Colorectal Disease, vol.2, issue.8, pp.999-1007, 2011. ,
DOI : 10.1007/s00384-011-1193-9
Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry, Journal of Gastroenterology, vol.1, issue.4, pp.359-65, 2012. ,
DOI : 10.1007/s00535-011-0499-2
Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis, World Journal of Gastroenterology, vol.11, issue.44, pp.7001-7007, 2005. ,
DOI : 10.3748/wjg.v11.i44.7001
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial., BMJ, vol.298, issue.6666, pp.82-88, 1989. ,
DOI : 10.1136/bmj.298.6666.82
Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis, World Journal of Gastroenterology, vol.12, issue.4, pp.520-525, 2006. ,
DOI : 10.3748/wjg.v12.i4.520
The Short Health Scale: A valid measure of subjective health in ulcerative colitis, Scandinavian Journal of Gastroenterology, vol.4, issue.10, pp.1196-203, 2006. ,
DOI : 10.1136/bmj.281.6240.581
The role and utility of faecal markers in inflammatory bowel disease, Therapeutic Advances in Gastroenterology, vol.8, issue.1, pp.23-36, 2015. ,
DOI : 10.1177/1756283X14553384
Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.41, issue.12, pp.1286-95, 2010. ,
DOI : 10.1111/j.1365-2036.2010.04295.x
URL : https://hal.archives-ouvertes.fr/inserm-00668856
A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis, Gastroenterology, vol.135, issue.2, pp.400-409, 2008. ,
DOI : 10.1053/j.gastro.2008.04.023
Granulocyte/Monocyte Adsorptive Apheresis in Moderate to Severe Ulcerative Colitis - Effective or Not, Digestion, vol.92, issue.1, pp.39-44, 2015. ,
DOI : 10.1159/000431149
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.3, issue.2, pp.47-91, 2009. ,
DOI : 10.1016/j.crohns.2009.02.010
Risk of Lymphoma Associated With Combination Anti???Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis, Clinical Gastroenterology and Hepatology, vol.7, issue.8, pp.874-81, 2009. ,
DOI : 10.1016/j.cgh.2009.01.004
The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis, Journal of Managed Care Pharmacy, vol.14, issue.1 Supp A, pp.2-12, 2008. ,
DOI : 10.18553/jmcp.2008.14.S1-A.1a
Patients' fears and unmet needs in inflammatory bowel disease, Alimentary Pharmacology and Therapeutics, vol.358, issue.9286, pp.54-63, 2004. ,
DOI : 10.1016/0163-8343(96)00036-9
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006. ,
DOI : 10.1136/gut.2005.082909